Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial

Clinical Cancer Research

Volumn 22, Issue 19, 2016, Pages 4870-4879

  Zhu, Andrew X ^a   Kang, Yoon Koo ^b   Rosmorduc, Olivier ^c   Evans, T R Jeffry ^d   Santoro, Armando ^e   Ross, Paul ^f   Gane, Edward ^g   Vogel, Arndt ^h   Jeffers, Michael ⁱ   Meinhardt, Gerold ⁱ   Peña, Carol E A ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETACELLULIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN 2; SORAFENIB; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN C; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84990944967     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2883     Document Type: Article

References (25)

1. World Health Organization. Cancer fact sheet N297. Available from: www.who.int/mediacentre/factsheets/fs297/en/.
2. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28: 3994-4005.
3. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2016. 2016. Available from: https://www.nccn.org/professionals/physiciangls/PDF/hepatobiliary.pdf.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P,Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
7. Lee YS, Seo SH, Yang BS, Lee JY. Synthesis and biological evaluation of bis (methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. Arch Pharm 2005;338:502-5.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
10. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
11. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67.
12. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
13. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66.
14. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9.
15. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
16. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805-11.
17. Li L, Guennel T, Marshall S, Cheung LW. A multi-marker molecular signature approach for treatment-specific subgroup identification with survival outcomes. Pharmacogenomics J 2014;14:439-45.
18. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, et al. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010;70:6233-7.
19. Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002;21: 1791-9.
20. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, et al. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 2013;32:16.
21. Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2013;2:209-15.
22. Yamaguchi R, Yano H, Nakashima O, Akiba J, Nishida N, Kurogi M, et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:152-60.
23. Xiang Z, Zeng Z, Tang Z, Fan J, Sun H,WuW, et al. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J 2009;15:519-25.
24. Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, et al. Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS One 2013;8:e64598.
25. Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120.